Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy

Phase 2

Not yet recruiting

• Conditions: Membranous Nephropathy
• Interventions: Drug: Peginterferon Alfa-2A 180 MCG/ML Injectable Solution

• Registration Number: NCT05941845
• Lead Sponsor: Centre Hospitalier Universitaire de Nice

Brief Summary

Membranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies. Current management is based on the use of immunosuppressive therapies. MN patients with a pro-inflammatory Th17 cytokine profile have a 10.5-fold increased risk of disease relapse. Interferon-based immunomodulatory therapies are effective in blocking the production of cytokines in the Th17 pathway avoiding an increased risk of infection, unlike immunosuppressive treatments. To date, these treatments have not been evaluated in the management of MN. The aims of the ALPHAGEM project are to monitor the immunological activity of the disease before and after 6 months of personalized interferon-alfa treatment in MN patients.

Detailed Description

Membranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies, in particular the anti-phospholipase A2 receptor antibodies (anti-PLA2R1). The development of these autoantibodies is the consequence of a genetic predisposition, environmental factors and a dysregulation of the immune response, with increased production of pro-inflammatory Th2 and Th17 cytokines. Current management is based on the use of immunosuppressive therapies to induce immunological remission, which precedes clinical remission. Disease relapse may occur in 5-28% of patients, and may be complicated by long-term renal failure. MN patients with a pro-inflammatory Th17 cytokine profile have a 10.5-fold increased risk of disease relapse. Rituximab induces the regulatory T pathway, but has no impact on the Th17 pathway. Interferon-based immunomodulatory therapies are effective in blocking the production of cytokines in the Th17 pathway avoiding an increased risk of infection, unlike immunosuppressive treatments. These treatments have been used for many years in the management of autoimmune diseases (such as multiple sclerosis for interferon beta) and viral infectious diseases (such as chronic hepatitis B for interferon alfa), affections where the Th17 pathway plays a key pathophysiological role. To date, these treatments have not been evaluated in the management of MN. The aims of the ALPHAGEM project are to monitor the immunological activity of the disease before and after 6 months of personalized interferon-alfa treatment in MN patients with immunological relapse and a Th17-type cytokine profile, and to assess drug tolerance.

Study Timeline

• Status Verified: 2023-06
• Study First Submitted: 2023-06-20
• Study First Submitted QC: 2023-07-04
• Last Update Submitted: 2023-07-04
• Study First Posted: 2023-07-12
• Last Update Posted: 2023-07-12
• Study Start: 2023-07-24
• Primary Completion: 2025-01-24
• Study Completion: 2025-07-24

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

1. Age 18 and above
2. Diagnosis of membranous nephropathy PLA2R1 antibodies-mediated
3. Immunological relapse (defined as an increase in anti-PLA2R1 antibody titer > 14 RU/mL after a phase of anti-PLA2R1 antibody negativation, i.e. immunological remission)
4. Plasma IL-17A levels > 73 pg/mL after non-specific stimulation of peripheral blood immune cells
5. Symptomatic anti-proteinuric treatment at a stable, maximum-tolerated dosage;
6. Patients with: (i) a platelet count≥ 90,000 cells/mm3; (ii) a neutrophil count ≥ 1500 cells/mm3; and (iii) appropriately monitored normal thyroid function (TSH and T4) at screening

Exclusion Criteria

1. Immunosuppressive treatment for MN in the 6 months before screening
2. Secondary MN (associated with cancer, infectious disease, autoimmune or iatrogenic disease)
3. Active nephrotic syndrome defined according to KDIGO guidelines by proteinuria > 3.5 g/day (or 3.5 g/g urine sample) and albuminemia < 30 g/L
4. Absence of previous immunological (anti-PLA2R1 antibodies < 14 RU/mL in ELISA or negative indirect immunofluorescence) and clinical (partial or complete) remission
5. Patients with a history of thrombosis or treated with anticoagulants
6. Pregnancy or breastfeeding
7. Cancer in treatment
8. Pre-existing retinopathy
9. Active and severe infections
10. Severe liver failure or cirrhosis
11. Pre-existing severe heart failure
12. Pre-existing psychiatric disorder or patient at risk of anxiety or depression (HAD Score > 11)
13. Patients who use or abuse substances
14. Hypersensitivity to active substance or excipients of study treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
6-month interferon alfa treatment	Peginterferon Alfa-2A 180 MCG/ML Injectable Solution	-

Primary Outcome Measures

Name	Time	Method
Membranous nephropathy immunological activity monitoring over 6-month interferon alfa treatment	18 months	Intra-individual variation in anti-PLA2R1 antibody titer (ELISA titer in RU/mL), before and after 6 months of treatment with IFN alfa

Secondary Outcome Measures

Name	Time	Method
Nephrotic syndrome monitoring over 6-month interferon alfa treatment	Baseline to Week 24	Intra-individual variation in albuminemia (g/L) under IFN alfa and stable symptomatic treatment
Immune response monitoring over 6-month interferon alfa treatment	Baseline to Week 24	Intra-individual variation in cytokine profile (assay of 1 cytokine in UI/ml: IFNγ) before and after 6 months of personalized treatment with IFN alfa
Clinical Tolerance monitoring over 6-month interferon alfa treatment	At Week 52	Percentage of Participants with clinical Adverse Events (AEs)
Biological Tolerance monitoring over 6-month interferon alfa treatment	At Week 52	Percentage of Participants with biological Adverse Events (AEs)

Trial Locations

Locations (1)

CHU de NICE; 🇫🇷 Nice, France